| Year |
Citation |
Score |
| 2023 |
Galan A, Papaluca A, Nejatie A, Matanes E, Brahimi F, Tong W, Hachim IY, Yasmeen A, Carmona E, Klein KO, Billes S, Dawod AE, Gawande P, Jeter AM, Mes-Masson AM, et al. GD2 and GD3 gangliosides as diagnostic biomarkers for all stages and subtypes of epithelial ovarian cancer. Frontiers in Oncology. 13: 1134763. PMID 37124505 DOI: 10.3389/fonc.2023.1134763 |
0.454 |
|
| 2019 |
Tong W, Maira M, Roychoudhury R, Galan A, Brahimi F, Gilbert M, Cunningham AM, Josephy S, Pirvulescu I, Moffett S, Saragovi HU. Vaccination with Tumor-Ganglioside Glycomimetics Activates a Selective Immunity that Affords Cancer Therapy. Cell Chemical Biology. PMID 31105061 DOI: 10.1016/J.Chembiol.2019.03.018 |
0.478 |
|
| 2015 |
Tong W, Maira M, Gagnon M, Saragovi HU. Ligands Binding to Cell Surface Ganglioside GD2 Cause Src-Dependent Activation of N-Methyl-D-Aspartate Receptor Signaling and Changes in Cellular Morphology. Plos One. 10: e0134255. PMID 26252487 DOI: 10.1371/journal.pone.0134255 |
0.499 |
|
| 2012 |
Tong W, Sprules T, Gehring K, Saragovi HU. Rational design of peptide ligands against a glycolipid by NMR studies. Methods in Molecular Biology (Clifton, N.J.). 928: 39-52. PMID 22956132 DOI: 10.1007/978-1-62703-008-3_4 |
0.549 |
|
| 2010 |
Tong W, Gagnon M, Sprules T, Gilbert M, Chowdhury S, Meerovitch K, Hansford K, Purisima EO, Blankenship JW, Cheung NK, Gehring K, Lubell WD, Saragovi HU. Small-molecule ligands of GD2 ganglioside, designed from NMR studies, exhibit induced-fit binding and bioactivity. Chemistry & Biology. 17: 183-94. PMID 20189108 DOI: 10.1016/J.Chembiol.2010.01.012 |
0.547 |
|
| Show low-probability matches. |